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ABSTRACT
Objectives: To describe laboratory abnormalities among HIV-infected women and their infants with 
standard and increased lopinavir/ritonavir (LPV/r) dosing during the third trimester of pregnancy. 
Methods: We evaluated data on pregnant women from NISDI cohorts (2002-2009) enrolled in Bra-
zil, who received at least 28 days of LPV/r during the third pregnancy trimester and gave birth to 
singleton infants. Results: 164 women received LPV/r standard dosing [(798/198 or 800/200 mg/
day) (Group 1)] and 70 increased dosing [(> 800/200 mg/day) (Group 2)]. Group 1 was more likely 
to have advanced clinical disease and to use ARVs for treatment, and less likely to have CD4 counts 
≥ 500 cells/mm3. Mean plasma viral load was higher in Group 2. There were statistically signifi-
cant, but not clinically meaningful, differences between groups in mean AST, ALT, cholesterol, and 
triglycerides. The proportion of women with Grade 3 or 4 adverse events was very low, with no 
statistically significant differences between groups in severe adverse events related to ALT, AST, total 
bilirubin, cholesterol, or triglycerides. There were statistically significant, but not clinically meaning-
ful, differences between infant groups in ALT and creatinine. The proportion of infants with Grade 
3 or 4 adverse events was very low, and there were no statistically significant differences in severe 
adverse events related to ALT, AST, BUN, or creatinine. Conclusion: The proportions of women and 
infants with severe laboratory adverse events were very low. Increased LPV/r dosing during the third 
trimester of pregnancy appears to be safe for HIV-infected women and their infants. 
Keywords: pregnancy; HIV; HIV protease inhibitors; drug toxicity.
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INTRODUCTION
Mother-to-child transmission (MTCT) is the 
primary means by which children acquire HIV 
infection. Development and implementation 
of efficacious interventions to prevent MTCT 
(including antiretroviral [ARV] prophylaxis, 
cesarean section before labor and before rup-
ture of membranes, and complete avoidance of 
breastfeeding), along with use of antiretroviral 
treatment by HIV-infected pregnant women 
who meet criteria for treatment, have resulted 
in the virtual elimination of MTCT in several 
areas of the world.1 
Several national guidelines recommend 
combination antiretroviral regimens for pre-
vention of MTCT of HIV and for the treat-
ment of maternal HIV infection itself.2-4 The 
combination of zidovudine (ZDV), lamivudine 
(3TC), and lopinavir/ritonavir (LPV/r) has be-
come a common ARV regimen for prevention 
of MTCT of HIV in Brazil and other countries.
In our analysis of data from The Eunice 
Kennedy Shriver National Institute of Child 
Health and Human Development (NICHD) 
International Site Development Initiative 
(NISDI) Perinatal Protocol, we examined the 
association between maternal ARV regimens 
used during pregnancy and infant preterm 
birth and low birth weight.5 Although use of 
a protease inhibitor-containing regimen dur-
ing pregnancy was not associated with an in-
creased risk of these adverse infant outcomes, 
we emphasized the importance of monitoring 
HIV-infected women and their children for 
potential adverse events associated with ma-
ternal use of ARVs during pregnancy. Recent-
ly, McArthur et al.6 reported twin preterm ne-
onates with cardiac toxicity related to LPV/r. 
The twins were born preterm (32 weeks gesta-
tion) to an HIV-infected mother. One of them 
developed complete heart block and dilated 
cardiomiopathy, while the other developed 
mild bradycardia.
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During pregnancy, changes in drug pharmacoki-
netics are induced through physiological variations.7-12 
Increased progesterone levels tend to affect drug absorp-
tion, which also may be impaired by higher gastric pH. 
Drug distribution is modified by elevated body water and 
fat, while increased renal blood flow may enhance the 
clearance of some drugs. Plasma albumin and alpha-acid 
glycoprotein concentrations are decreased, potentially af-
fecting protein binding. There may be concomitantly in-
creased distribution, metabolism and excretion.13 Finally, 
the expression of cytochrome P-450 is highly variable 
during pregnancy,14 with potential consequences for the 
metabolism of many drugs, including protease inhibitors 
(PIs). Transplacental passage of PIs is generally low and 
cord blood PI concentrations are undetectable in most in-
fants born to mothers receiving PIs.15
Plasma concentrations of LPV/r are reduced dur-
ing the third trimester of gestation [Area Under the 
Curve (AUC) and trough levels (Cmin)].7-10,12 Thus, an in-
crease in LPV/r dose during the third trimester for both 
LPV/r-experienced and -naïve HIV-infected pregnant 
women or serum therapeutic drug monitoring (TDM)2-
3,12 have been endorsed by some experts. In a recent 
United States-based study, Best et al.16 suggested that the 
higher LPV/r dose should be used in second and third 
trimester pregnant women, especially those who are 
PI-experienced, and that postpartum LPV/r dosing can 
be reduced to standard dosing within two weeks after de-
livery. However, higher dosing during the third trimester 
could be associated with the development of toxicities af-
fecting both mother and infant, leading to lower adher-
ence. There is limited information regarding maternal 
and infant adverse events with higher third trimester dos-
ing. The objective of this study was to describe the occur-
rence of laboratory adverse events according to standard 
and increased LPV/r dosing during the third trimester of 
pregnancy in HIV-infected women and their infants.
MATERIAL AND METHODS
The study population comprised HIV-infected preg-
nant women enrolled in the Eunice Kennedy Shriver 
National Institute of Child Health and Human Develop-
ment (NICHD) International Site Development Initiative 
(NISDI) Perinatal or Longitudinal Study in Latin American 
Countries (LILAC) protocols, who received LPV/r during 
the third trimester of pregnancy, and their infants. The 
NISDI Perinatal and NISDI LILAC protocols are prospec-
tive cohort studies that enrolled HIV-infected pregnant 
women and their infants at multiple sites in Argentina, the 
Bahamas, Brazil, Jamaica, Mexico, and Peru beginning in 
2002 (NISDI Perinatal) and in 2008 (NISDI LILAC).17 Par-
ticipant follow-up continued for at least six months after 
delivery/birth (last maternal laboratory assays obtained 
at 6-12 weeks postpartum in the NISDI Perinatal Proto-
col). Choice and dosing of ARVs was at the discretion of 
each subject’s physician. All women enrolled in the stud-
ies provided written informed consent, and the protocols 
were approved at local institutional review boards (IRBs), 
as well as the IRBs at NICHD and Westat.
Since the majority (61%) of the NISDI/LILAC enroll-
ments occurred in Brazil and few subjects at sites in the 
other countries used increased dosing of LPV/r, data were 
only analyzed for participants from Brazil. Other inclusion 
criteria were: enrolled through December 31st, 2009; first 
on-study pregnancy; known pregnancy outcome that was 
a singleton birth; reached the third trimester of pregnancy; 
used LPV/r in the third trimester for at least 28 days; and 
received LPV/r standard [798/198 mg/day (soft gel cap-
sules) or 800/200 mg/day (hard capsules)] or increased 
doses (> 800/200 mg/day) during the third trimester.
Maternal and infant adverse events were assessed ac-
cording to standard or increased LPV/r dosages dur-
ing the third trimester. Statistical analyses for categorical 
comparisons were performed using the Fisher’s exact test 
and the Student’s t test for comparison of means. Analyses 
were performed using SAS statistical software version 9.1; 
p-values < 0.05 were considered to be significant.
RESULTS
Overall, 1,630 pregnancies occurred among women en-
rolled in the cohorts through the end of 2009, 1,000 of 
whom were from Brazil. Of these, 966 women were enrolled 
for the first time and had known pregnancy outcomes. Of 
the 966 subjects, 944 used ARVs during the third trimes-
ter of pregnancy and had singleton births. Of these, 291 
used LPV/r during the third trimester, and 234 subjects 
received standard or increased doses of LPV/r for at least 
28 days. Therefore, the study population comprised 234 
HIV-infected women and their infants. Of the 234 women, 
164 (70.1%) used standard LPV/r dosing (Group 1) (medi-
an duration of use: 76 days) and 70 (29.9%) used increased 
dosing (Group 2) (median duration of use: 67 days).
Maternal variables are presented in Tables 1 and 2. Moth-
ers in Group 1 were older than those in Group 2 (p = 0.002). 
A larger proportion of women in Group 1 compared to 
Group 2 were classified as CDC clinical disease stage B/C 
at both enrollment and hospital discharge (p = 0.0008 and 
p = 0.002, respectively). A larger proportion of mothers 
in Group 1 received ARVs for treatment (vs. prophylaxis) 
than in Group 2 (p = 0.02). A smaller proportion of women 
in Group 1 than Group 2 had CD4 counts of 500 cells/mm3 
or more at enrollment (p = 0.04) (Table 1). Although the 
proportion of subjects with a CD4 count at enrollment of 
500 cells/mm3 or more differed by group, the mean CD4 
count did not differ between groups at enrollment or at 
hospital discharge (p > 0.2) (Table 2), and, although the 
Lopinavir/ritonavir in pregnancy
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Table 1. Maternal categorical variables by LPV/r dosing group
  Standard dosing Increased dosing  
 Characteristic (Group 1)  (Group 2) p-value 
  n = 164 (%) n = 70 (%)
Age at delivery (years)
	 ≤	29	 80	(48.8)	 50	(71.4)	
0.002
 >29 84 (51.2) 20 (28.6)
Education (completed years)
 0-6 54 (32.9) 23 (32.9) 
1.00
 7+ 110 (67.1) 47 (67.1) 
Number of people in household
 1-3 79 (48.2) 36 (51.4) 
0.67
	 ≥	4	 85	(51.8)	 34	(48.6)
Gainful employment outside the home
 Yes 65 (39.6) 20 (28.6) 
0.14
 No  99 (60.4) 50 (71.4)
Tobacco use during pregnancy
 Yes 47 (28.7) 21 (30.0) 
0.88
 No 117 (71.3) 49 (70.0)
Alcohol use during pregnancy
 Yes 35 (21.3) 11 (15.7) 
0.37
 No 129 (78.7) 59 (84.3)
Cocaine use during pregnancy
 Yes 8 (4.9) 1 (1.4) 
0.29
 No 156 (95.1) 69 (98.6)
Marijuana use during pregnancy
 Yes 5 (3.0) 3 (4.3) 
0.70
 No 159 (97.0) 67 (95.7)
Any substance use during pregnancy
 Yes 63 (38.4) 25 (35.7) 
0.77
 No 101 (61.6) 45 (64.3)
CDC clinical disease stage at enrollment
 A  129 (78.7) 67 (95.7) 
0.0008
 B or C  35 (21.3) 3 (4.3)
CDC clinical disease stage at hospital discharge
 A  128 (78.0) 66 (94.3) 
0.0021
 B or C 36 (22.0) 4 (5.7)
Reason for ARV use during pregnancy
 Prophylaxis  71 (45.5) 43 (62.3)
 Treatment  85 (54.5) 26 (37.7) 0.02
 Missing* 8 1
CD4 count at enrollment (cells/mm3)
 <500 100 (61.0) 32 (45.7) 
0.04
	 ≥500	 64	(39.0)	 38	(54.3)
CD4 count at hospital discharge (cells/mm3)
 <500 75 (46.9) 26 (40.6)
	 ≥500	 85	(53.1)	 38	(59.4)	 0.46
 Missing* 4 6
Plasma viral load at enrollment (copies/mL)
 < 1,000 112 (71.8) 53 (75.7) 
	 ≥	1,000	 44	(28.2)	 17	(24.3)	 0.63
 Missing* 8 0
Peixoto, Pilotto, Stoszek et al.
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Table 1. Maternal categorical variables by LPV/r dosing group
  Standard dosing Increased dosing  
 Characteristic (Group 1)  (Group 2) p-value 
  n = 164 (%) n = 70 (%)
Plasma viral load at hospital discharge (copies/mL)
 < 1,000 137 (87.8) 53 (84.1)
	 ≥	1,000	 19	(12.2)	 10	(15.9)	 0.51
 Missing* 8 7
CD4 count increase (enrollment to hospital discharge)  
(cells/mm3)
 Yes 109 (68.1) 47 (73.4)
 No  51 (31.9) 17 (26.6) 0.52
 Missing* 4 6
Plasma viral load decrease (enrollment to hospital discharge)  
(copies/mL)
 Yes 48 (31.6) 22 (34.9)
 No 104 (68.4) 41 (65.1) 0.64
 Missing* 12 7
ALT at enrollment (IU/L)
	 ≤	Grade	2		 162	(100.0)	 70	(100.0)
 Grade 3/4 0 (0.0) 0 (0.0) NC
 Missing* 2 0
ALT at 6-12 weeks postpartum (IU/L)
	 ≤	Grade	2	 161	(99.4)	 68	(100.0)
 Grade 3/4 1 (0.6) 0 (0.0) 1.00
 Missing* 2 2
AST at enrollment (IU/L)
	 ≤	Grade	2	 162	(100.0)	 70	(100.0)	
 Grade 3/4 0 (0.0) 0 (0.0) NC
 Missing* 2 0
AST at 6-12 weeks postpartum (IU/L)
	 ≤	Grade	2	 161	(99.4)	 68	(100.0)
 Grade 3/4 1 (0.6) 0 (0.0) 1.00
 Missing* 2 2
Total bilirubin at enrollment (mg/dL)
	 ≤	Grade	2	 160	(100.0)	 70	(100.0)
 Grade 3/4 0 (0.0) 0 (0.0) NC
 Missing* 4 0
Total bilirubin at 6-12 weeks postpartum (mg/dL)
	 ≤	Grade	2	 161	(100.0)	 67	(98.5)
 Grade 3/4 0 (0.0) 1 (1.5) 0.30
 Missing* 3 2
Cholesterol at enrollment (mg/dL)
	 ≤	Grade	2	 158	(97.5)	 64	(91.4)
 Grade 3/4 4 (2.5) 6 (8.6) 0.07
 Missing* 2 0
Cholesterol at 6-12 weeks postpartum (mg/dL)
	 ≤	Grade	2	 157	(96.9)	 68	(100.0)
 Grade 3/4 5 (3.1) 0 (0.0) 0.32
 Missing* 2 2
Triglycerides at enrollment (mg/dL)
	 ≤	Grade	2	 161	(99.4)	 70	(100.0)
 Grade 3/4 1 (0.6) 0 (0.0) 1.00
 Missing* 2 0
Lopinavir/ritonavir in pregnancy
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Table 2. Maternal continuous variables by LPV/r dosing group
 Standard dosing Increased dosing  
Characteristic (Group 1) (Group 2) p-value 
 Mean (SD) Mean (SD)
Age at delivery (years) 29.6 (5.5) 27.1 (6.4) 0.004
CD4 count at enrollment (cells/mm3) 486.1 (292.7) 535.4 (303.9) 0.24
CD4 count at hospital discharge (cells/mm3)  559.6 (292.0) 605.8 (307.5) 0.29
Log HIV RNA at enrollment (copies/mL) 2.6 (1.0) 3.0 (0.7) 0.007
Log HIV RNA at hospital discharge (copies/mL) 2.3 (0.8) 2.8 (0.7) 0.0002
ALT at enrollment (IU/L) 15.8 (14.9) 14.1 (11) 0.34
ALT at 6-12 weeks postpartum (IU/L) 24.1 (22.7) 17.2 (9.0)  0.001
AST at enrollment (IU/L) 21.5 (19.4) 19.6 (9.5) 0.32
AST at 6-12 weeks postpartum (IU/L) 26.4 (33.6) 19.9 (6.5) 0.02
Total bilirubin at enrollment (mg/dL) 0.5 (0.3) 0.5 (0.3) 0.63
Total bilirubin at 6-12 weeks postpartum (mg/dL) 0.5 (0.3) 0.6 (0.6) 0.72
Cholesterol at enrollment (mg/dL) 204.5 (42.1) 220.4 (53.2) 0.03
Cholesterol at 6-12 weeks postpartum (mg/dL) 186.8 (46.3) 178.6 (37.1) 0.15
Triglycerides at enrollment (mg/dL) 231.6 (106.4) 235.4 (93) 0.80
Triglycerides at 6-12 weeks postpartum (mg/dL) 152.6 (77.7) 125.5 (63.5) 0.01
p-values calculated using Student’s t test for comparison of means.
Table 1. Maternal categorical variables by LPV/r dosing group
Characteristic Standard dosing Increased dosing  
  (Group 1)  (Group 2) p-value 
  n = 164 (%) n = 70 (%)
Triglycerides at 6-12 weeks postpartum (mg/dL)
	 ≤	Grade	2	 162	(100.0)	 68	(100.0)
 Grade 3/4 0 (0.0) 0 (0.0) NC
 Missing* 2 2
p-values calculated using Fisher’s exact test; * missing data; NC, not calculated.
mean plasma viral load was significantly higher in Group 
2 at enrollment (p = 0.007) and at the hospital discharge 
(p = 0.0002) (Table 2), there were no statistically significant 
differences in the percentages of subjects with viral loads 
≥ 1,000 copies/mL at enrollment or at hospital discharge. 
Similarly, the percentage of subjects whose plasma viral 
load decreased from enrollment to hospital discharge was 
not different between groups (Table 1). 
At enrollment, women in Group 2 had higher mean cho-
lesterol values (p = 0.03). At 6-12 weeks postpartum, women 
in Group 1 had higher mean alanine aminotransferase (ALT) 
(p = 0.001), aspartate aminotransferase (AST) (p = 0.02), and 
triglyceride (p = 0.01) values (Table 2). The overall propor-
tion of women with Grade 3 or 4 adverse events was very low 
(≤ 1.5%, except cholesterol 8.6%), and there were no statisti-
cally significant differences between the proportions of women 
in each group with Grade 3 or 4 adverse events related to ALT, 
AST, total bilirubin, cholesterol, or triglycerides (Table 1). 
Infant variables are shown in Tables 3 and 4. There 
were no statistically significant differences in gesta-
tional age, birth weight, gender, or HIV infection sta-
tus according to standard versus increased dose of LPV/r 
(Table 3). As shown in Table 4, infants born to mothers in 
Group 1 had significantly higher mean ALT values at birth 
(p = 0.0006), and creatinine values at birth and at 6-12 weeks 
(p < 0.0001). The overall proportion of infants with Grade 3 or 
4 adverse events was very low (≤ 1.9%), and there were no sta-
tistically significant differences in the proportions of infants 
in each group with Grade 3 or 4 adverse events related to ALT, 
AST, blood urea nitrogen (BUN), or creatinine (Table 3). 
Peixoto, Pilotto, Stoszek et al.
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Table 3. Infant categorical variables by maternal LPV/r dosing group
Characteristic Standard dosing Increased dosing  
  (Group 1)  (Group 2) p-value 
  n = 164 (%) n = 70 (%)
Gestational age at birth (completed weeks)
 <37  16 (9.8) 6 (8.7)
	 ≥37		 147	(90.2)	 63	(91.3)	 1.00
 Missing* 1 1
Birth weight (grams)
 <2,500  33 (20.2) 11 (15.9)
	 ≥2,500		 130	(79.8)	 58	(84.1)	 0.58
 Missing* 1 1
Gender
 Female 77 (47.2) 32 (46.4)
 Male 86 (52.8) 37 (53.6) 1.00
 Missing* 1 1
HIV infection status
 Infected 1 (0.6) 0 (0.0)
 Uninfected 129 (79.6) 56 (81.2)
 1.00
 Indeterminate 32 (19.8) 13 (18.8)
 Missing* 2 1
ALT at birth (IU/L)
	 ≤	Grade	2	 158	(100.0)	 63	(100.0)
 Grade 3/4 0 (0.0) 0 (0.0) NC
 Missing* 6 7
ALT at 6-12 weeks of age (IU/L)
	 ≤	Grade	2	 159	(98.8)	 63	(98.4)
 Grade 3/4 2 (1.2) 1 (1.6) 1.00
 Missing* 3 6
AST at birth (IU/L)
	 ≤	Grade	2	 155	(98.1)	 61	(98.4)
 Grade 3/4 3 (1.9) 1 (1.6) 1.00
 Missing* 6 8
AST at 6-12 weeks of age (IU/L)
	 ≤	Grade	2	 160	(99.4)	 64	(100.0)
 Grade 3/4 1 (0.6) 0 (0.0) 1.00
 Missing* 3 6
BUN at birth (mg/dL)
	 ≤	Grade	2	 124	(100.0)	 61	(100.0)
 Grade 3/4 0 (0.0) 0 (0.0) NC
 Missing* 40 9
BUN at 6-12 weeks of age (mg/dL)
	 ≤	Grade	2	 125	(98.4)	 62	(100.0)
 Grade 3/4 2 (1.6) 0 (0.0) 1.00
 Missing* 37 8
Creatinine at birth (mg/dL)
	 ≤	Grade	2	 125	(100.0)	 60	(100.0)
 Grade 3/4 0 (0.0) 0 (0.0) NC
 Missing* 39 10
Lopinavir/ritonavir in pregnancy
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Table 3. Infant categorical variables by maternal LPV/r dosing group
Characteristic Standard dosing Increased dosing  
  (Group 1)  (Group 2) p-value 
  n = 164 (%) n = 70 (%)
Creatinine at 6-12 weeks of age (mg/dL)
	 ≤	Grade	2	 127	(100.0)	 62	(100.0)
 Grade 3/4 0 (0.0) 0 (0.0) NC
 Missing* 37 8
p-values calculated using Fisher’s exact test; * missing data; NC, not calculated.
Table 4. Infant continuous variables by LPV/r dosing group
Characteristic Standard dosing Increased dosing  
 (Group 1) (Group 2) p-value 
 Mean (SD) Mean (SD)
ALT at birth (IU/L) 19.0 (9.4) 15.4 (5.9) 0.0006
ALT at 6-12 weeks of age (IU/L) 35.8 (35.9) 28.6 (33.5) 0.16
AST at birth (IU/L) 65.0 (36.5) 59.1 (29.4) 0.26
AST at 6-12 weeks of age (IU/L) 43.5 (26.6) 40.3 (22.9) 0.40
BUN at birth (mg/dL) 9.3 (6.6) 9.7 (7.0) 0.76
BUN at 6-12 weeks of age (mg/dL) 13.3 (9.3) 14.7 (9.8) 0.33
Creatinine at birth (mg/dL) 0.7 (0.2) 0.5 (0.2) < 0.0001
Creatinine at 6-12 weeks of age (mg/dL) 0.4 (0.1) 0.3 (0.1) < 0.0001
p-values calculated using Student’s t test for comparison of means.
DISCUSSION
Since most studies of LPV/r have been performed in re-
source-rich settings, among ARV-naïve, non-pregnant 
adults or ARV-experienced subjects, extrapolation to other 
populations may be limited by differences in genetics, diet, 
concomitant comorbidities, and other factors. For this rea-
son, we undertook this analysis of laboratory adverse events 
among HIV-infected pregnant women and their infants in 
Brazil according to LPV/r dosing during the third trimes-
ter of pregnancy. In this analysis, most women (70.1%) used 
standard LPV/r dosing during the third trimester of preg-
nancy and the median duration of use of either standard 
or increased dosing of LPV/r was over two months. Wom-
en in the standard dosing group were more likely to have 
more advanced clinical disease and to have used ARVs 
for treatment. They were less likely to have CD4 counts 
of 500 cells/mm3 or more. The mean plasma viral load was 
higher in the increased dosing group. Although there were 
statistically significant differences between groups in terms 
of mean AST, ALT, cholesterol, and triglyceride values, none 
of these differences were clinically meaningful. The over-
all proportion of women with Grade 3 or 4 adverse events 
was very low, and there were no statistically significant dif-
ferences in the proportions of women in each group with 
severe adverse events related to ALT, AST, total bilirubin, 
cholesterol, or triglycerides. Although there were statisti-
cally significant differences between infant groups in terms 
of ALT and creatinine values, none of these differences were 
clinically meaningful. The overall proportion of infants with 
Grade 3 or 4 adverse events was very low, and there were 
no statistically significant differences in the proportions of 
infants in each group with severe adverse events related to 
ALT, AST, BUN, or creatinine. 
Lipid abnormalities and elevations in liver enzyme con-
centrations have been associated with use of LPV/r. Like 
other PIs, LPV/r may cause significant lipid elevations and 
fat redistribution. Hypertriglyceridemia and hypercholes-
terolemia were the most frequently observed laboratory ab-
normalities in LPV/r recipients in clinical trials and may be 
the reason for discontinuation of therapy in some HAART-
experienced patients.18 Increases in total cholesterol and 
Peixoto, Pilotto, Stoszek et al.
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triglycerides are seen within the first month of starting 
therapy and are relatively stable after this time.19 Total 
Grade 3 and 4 cholesterol and triglyceride elevations ap-
pear to occur more frequently in PI-experienced than in 
PI-naive LPV/r-treated patients. Some trials have found 
that the lipid derangements caused by LPV/r were more 
severe than those caused by other PIs such as atazanavir, 
atazanavir/ritonavir, or nelfinavir,20,21 but other trials re-
ported similar elevations in triglycerides and cholesterol in 
LPV/r recipients as compared to subjects receiving other 
PIs.22 PIs including LPV/r have been associated with insu-
lin resistance, new onset diabetes, and worsening of pre-
existing diabetes requiring hypoglycemic agents in some 
patients. LPV/r can cause transient elevations in transami-
nase levels, but these are usually not clinically meaningful. 
The incidence of severe hepatic events in patients receiv-
ing LPV/r is very low. Hepatitis C coinfection and baseline 
elevations in transaminases may be associated with severe 
liver events in LPV/r recipients.23 Robbins et al.24 published 
data showing that doses of LPV/r higher than those cur-
rently approved by the FDA are safe and well tolerated for 
up to 48 weeks in children and adolescents with HIV infec-
tion. There was no significant increase in plasma triglycer-
ides, and while there was an initial statistically significant 
increase in cholesterol, this was of modest size and did not 
worsen over the course of the study. There was no evidence 
of hepatic or cardiac toxicity with these higher doses. 
A French study explored whether LPV/r exposure dur-
ing pregnancy was associated with adverse outcomes.25 
For each HIV-infected woman, two uninfected women 
matched by age, parity and geographical origin were selected 
among patients delivering during the same period. Rates of 
placental complications and gestational glucose intolerance 
were not higher among HIV-infected women than in con-
trols. However, the rate of preterm birth was higher among 
HIV-infected women (21%) than among controls (10%) 
(p < 0.01). 
One of the strengths of our study is that it is a large mul-
ticenter cohort that includes prospectively collected data. 
Women and children were enrolled and followed at the same 
health care facility at each site, where they received primary 
HIV and other medical care, and it is unlikely that any im-
portant clinical and laboratory events were missed among 
those retained in care. The observational study design is a 
limitation, in that women were prescribed LPV/r standard 
dose vs. higher dose by their physicians (and not by rand-
omization). In addition, the women enrolled in Group 1 on 
average were older, more likely to be using ARVs for treat-
ment (rather than prophylaxis), and appeared to have more 
advanced HIV disease (more women at CDC clinical dis-
ease stage B/C at both enrollment and hospital discharge) 
than women in Group 2. However, given the low adverse 
event rates for both mothers and infants in the entire study 
population, these baseline differences between the two dose 
groups are unlikely to affect the main findings of our analy-
sis. Finally, adherence data were not collected as part of the 
Perinatal Protocol (2002-2007, but were during the LILAC 
Protocol (2008-current). 
In summary, in this population of HIV-infected 
women and their infants in Brazil, the proportions of 
subjects with severe laboratory adverse events were very 
low. These results suggest that increased LPV/r dosing 
during the third trimester of pregnancy is safe for both 
HIV-infected women and their infants. Further assess-
ments of LPV/r dosing during pregnancy and maternal/
infant adverse events are warranted.
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